Pharmaceutical
– Potent, uncompetitive inhibitors of the pro-degenerative NADase SARM1 reported – Molecular basis of product-assisted inhibition of NAD hydrolases like SARM1 and CD38 that have been implicated in neurological diseases elucidated – Research supports Nura Bio’s goal of entering First-in-Human trials with oral, brain-penetrant SARM1 inhibitors in early 2023 Excerpt from the Press Release: SOUTH…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the publication of preclinical data showing the effect of sodium phenylbutyrate (PB) and taurursodiol (TURSO, also known as ursodoxicoltaurine) on the transcriptomic and metabolomic profiles of primary skin fibroblasts from adults with sporadic amyotrophic lateral sclerosis (ALS)…
Read More
Second region now open for enrolment for rare, rapidly progressive, neurodegenerative disease Excerpt from the Press Release: MELBOURNE, Australia and SAN FRANCISCO, Aug. 25, 2022 /PRNewswire/ — Alterity Therapeutics (ASX: ATH,NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the Company’s Phase 2 clinical trial of…
Read More
First in human study demonstrates positive safety and tolerability profile for MapLight’s M1/M4 muscarinic agonist therapy Excerpt from the Press Release: SAN FRANCISCO, Aug. 18, 2022 /PRNewswire/ — MapLight Therapeutics today announced it has completed its Phase 1 clinical trial evaluating ML-007, the second clinical compound developed using the MapLight platform. ML-007 is an M1/M4…
Read More
– Phase 3 MANTRA trial completed enrollment five months ahead of previous guidance – – MANTRA topline data anticipated in 1H 2023 – – Management to host 2Q 2022 Earnings Call today at 5:00 PM Eastern Time – Excerpt from the Press Release: NEWARK, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) — Rain Therapeutics Inc. (NasdaqGS:…
Read More
– REACH is the first Phase 3 trial for this rare, progressive, and debilitating muscular disease –– Losmapimod is an oral small molecule that has the potential to be the first therapy to treat FSHD, the second most common form of muscular dystrophy –– U.S. Food and Drug Administration (FDA) granted Fast Track Designation in 2021 –…
Read More
– Codiak’s engineered exosome candidates demonstrate potential for best-in-class profile, with tumor retention and delivery to the cells of interest allowing for increased therapeutic window – – exoSTING and exoIL-12 demonstrated favorable safety and tolerability profile at repeat doses tested and antitumor activity was observed in both injected and uninjected/distal lesions – – Codiak has…
Read More
Publication highlights ability of Cas-CLOVER to perform multiplexed gene editing to produce allogeneic products with a high percentage of Tscm cells that may result in better tolerability and deeper clinical responses Cas-CLOVER has demonstrated lower off-target and translocation activity than other published technologies including CRISPR, TALENs and Base Editors Excerpt from the Press Release: SAN…
Read More
Excerpt from the Press Release: LA JOLLA, Calif., June 29, 2022 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA), part of…
Read More
Excerpt from the Press Release: LA JOLLA, Calif., June 22, 2022 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will initiate a comprehensive research collaboration with Juntendo University, School of Medicine…
Read More